NASDAQ:CLSN
Delisted
Celsion Corporation Stock News
$1.56
+0.0600 (+4.00%)
At Close: Jan 27, 2023
Mid-Morning Market Update: Markets Fall; Alibaba Earnings Beat Estimates
02:12pm, Friday, 22'nd May 2020Celsion: Big Gains Possible In July (NASDAQ:CLSN)
01:09am, Wednesday, 20'th May 2020
Celsion's ThermoDox Phase 3 trial will release second interim data in July 2020. ThermoDox, if approved, would treat kidney cancer, a huge opportunity. The tria
Celsion shares are trading lower after the company reported worse-than-expected Q1 EPS results.
12:41pm, Friday, 15'th May 2020Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update
12:00pm, Friday, 15'th May 2020
Phase III OPTIMA Study on Track for Interim Data Analysis in July Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J, May 15, 2020 -- Celsion.
Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020
01:00pm, Friday, 08'th May 2020
Celsion Corporation (CLSN) announced today that the Company will host a conference call to discuss financial results for the first quarter ended March 31, 2020 and provide an update on its development
Celsion Corporation to Hold First Quarter —…—… Financial Results Conference Call on ...
12:00am, Friday, 08'th May 2020
Celsion Corporation (CLSN), an oncology drug development company, today announced it has received $1.82 million of net cash proceeds from the sale of approximately $1.9 million of its unused New Jerse
VÉLIZY-VILLACOUBLAY, France — April 23, 2020 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA) announces IFRS unaudited financial results for the first quarter ended March.
If You Had Bought Celsion (NASDAQ:CLSN) Stock Five Years Ago, You'd Be Sitting On A 97% Loss, Today
02:04pm, Friday, 17'th Apr 2020
Celsion Corporation (NASDAQ:CLSN) shareholders will doubtless be very grateful to see the share price up 63% in the...
Dublin, April 17, 2020 -- The "Nucleic Acid Based Gene Therapy Market Global Report 2020-30" report has been added to ResearchAndMarkets.com's offering. The.
Celsion Corporation (CLSN), an oncology drug-development company, announces that the prescribed minimum number of events of 158 patient deaths has been reached for the second pre-specified interim ana
